<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The burden of <z:hpo ids='HP_0002020'>gastroesophageal reflux disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) results from its widespread prevalence and the unfavorable impact of its symptoms on well-being and quality of life </plain></SENT>
<SENT sid="1" pm="."><plain>Whereas abnormalities of the antireflux barrier (lower esophageal sphincter) are important in the pathophysiology of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, pharmacologic therapy for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> is based on suppression of acid, which is responsible for the majority of the symptoms and for epithelial damage </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="49200">Proton pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPIs</z:chebi>) are the agents of choice for achieving the goals of medical therapy in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>, which include symptom relief, improvement in quality of life, and healing and prevention of mucosal injury </plain></SENT>
<SENT sid="3" pm="."><plain>As a class, these drugs are extremely safe </plain></SENT>
<SENT sid="4" pm="."><plain>The newest <z:chebi fb="4" ids="53266">PPI</z:chebi>, <z:chebi fb="0" ids="50275">esomeprazole</z:chebi>, brings a statistically significant increase in healing of mucosal injury and symptom relief in patients with erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, compared with <z:chebi fb="14" ids="7772">omeprazole</z:chebi> and <z:chebi fb="0" ids="6375">lansoprazole</z:chebi> </plain></SENT>
<SENT sid="5" pm="."><plain>This article reviews the role of medical therapy in the short- and long-term management of symptomatic patients with or without erosive <z:hpo ids='HP_0100633'>esophagitis</z:hpo>, including extraesophageal presentations, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> during pregnancy, and <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Management of refractory patients is addressed </plain></SENT>
</text></document>